JAK2 and acute erythroid leukemia: Mechanistic studies suggest that N2′s activity may be mediated by dual activation of JAK2/STAT3 and PKCδ/MAPK signaling via targeting JAK2, representing a novel mechanism of action in differentiation therapy for AEL.